Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Current and future HER2+, HR- metastatic breast cancer treatment approaches

Wolfgang Janni • 14 Sep 2024
ESMO 2024
Breast Cancer Antibodies Docetaxel Paclitaxel Pertuzumab Ribociclib Trastuzumab
DETECT V

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses current treatments for HER2-positive, HR-positive metastatic breast cancer (mBC), which includes taxane-based chemotherapy (paclitaxel and docetaxel) with dual HER2 blockade (pertuzumab and trastuzumab), the standard of care for HER2+, HR- mBC. The Phase III DETECT V trial (NCT02344472) explores an alternative approach, combining HER2-targeted therapy with endocrine treatment, avoiding upfront chemotherapy. The study amendment introduces ribociclib in both treatment arms, potentially enhancing outcomes for patients with HER2-positive, HR-positive mBC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wolfgang Janni

Using ctDNA in breast cancer clinical trials
2:09
Using ctDNA in breast cancer clinical trials
Wolfgang Janni • 13 Mar 2025
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
2:19
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
Wolfgang Janni • 13 Mar 2025
The emerging role of ctDNA in screening & monitoring early breast cancer
0:41
The emerging role of ctDNA in screening & monitoring early breast cancer
Wolfgang Janni • 13 Mar 2025
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
1:44
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
Wolfgang Janni • 13 Mar 2025

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals